通过NF-κB信号通路和调节肠道微生物群,减弱DSS诱导的性结肠炎
Xiaojun Song1, Wei Wang1, Li Liu1
1School of Pharmacy, Wannan Medical College, Wuhu 241002, China.
Molecules (Basel, Switzerland)
|May 11, 2024
概括
波利亚可可斯 (PC) 通过减少炎症,修复肠道屏障和改善肠道微生物群,有效治疗性结肠炎 (UC). 这项研究阐明了PC.
科学领域:
- 药理学和胃肠病学 药理学和胃肠病学
- 自然产品研究自然产品研究
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种具有重大全球健康影响的慢性炎症疾病.
- 对于UC的Poria cocos (PC) 的治疗机制尚未完全理解.
- 确定活性成分和阐明PC在UC中的作用至关重要.
研究的目的:
- 在性结肠炎 (UC) 的小鼠模型中研究Poria cocos (PC) 的治疗效果和潜在机制.
- 为了确定Poria cocos.中的关键活性成分.
- 评估PC对肠道炎症,屏障功能和肠道微生物群的影响.
主要方法:
- 使用LC-MS/MS来识别Poria cocos.中的成分.
- 用德克斯硫酸 (DSS) 诱导的UC小鼠模型来评估PC的保护作用.
- 进行了疾病活动指数 (DAI),结肠长度和组织学分析.
- 通过ELISA,qPCR和西部斑点测试,评估了炎症标志物和NF-κB通路.
- 紧结蛋白 (ZO-1,Claudin-1) 的表达通过西式涂抹和免疫组织化学进行了评估.
- 16S rRNA测序分析了肠道微生物群的组成.
主要成果:
- 在Poria cocos.中确定了52种营养素和活性成分.
- PC治疗显著缓解了UC症状,包括体重减轻,结肠缩短和减少DAI得分.
- 通过抑制NF-κB通路,PC抑制了炎症性细胞因子 (TNF-α,IL-6,IL-1β).
- PC恢复了紧结蛋白 (ZO-1,Claudin-1),增强了肠道屏障的完整性.
- PC促进了有益的肠道微生物群的多样性和丰富性.
结论:
- 波利亚可可通过减少NF-κB信号传递和减轻炎症损伤来改善性结肠炎症状.
- PC治疗通过恢复紧密结合蛋白来修复肠道屏障功能.
- 波利亚可可斯积极调节肠道微生物群的组成,有助于其在UC的治疗作用.
相关概念视频
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
382
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
382
01:17Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
01:17Chronic Bowel Disorders: Introduction
445
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
445
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
166
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
166
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
01:30Peptic Ulcer Disease I: Introduction
164
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
164